Department of Internal Medicine, Division of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya 6638136, Japan.
Center for Clinical Research and Education, Hyogo College of Medicine, Nishinomiya 6638136, Japan.
Int J Mol Sci. 2020 Jul 24;21(15):5254. doi: 10.3390/ijms21155254.
Sarcopenia in patients with liver cirrhosis (LC) has been attracting much attention these days because of the close linkage to adverse outcomes. LC can be related to secondary sarcopenia due to protein metabolic disorders and energy metabolic disorders. LC is associated with profound alterations in gut microbiota and injuries at the different levels of defensive mechanisms of the intestinal barrier. Dysbiosis refers to a state in which the diversity of gut microbiota is decreased by decreasing the bacterial species and the number of bacteria that compose the gut microbiota. The severe disturbance of intestinal barrier in LC can result in dysbiosis, several bacterial infections, LC-related complications, and sarcopenia. Here in this review, we will summarize the current knowledge of the relationship between sarcopenia and dysbiosis in patients with LC.
目前,由于与不良预后密切相关,肝硬化(LC)患者的肌肉减少症引起了广泛关注。LC 可继发于蛋白质代谢紊乱和能量代谢紊乱导致的继发性肌肉减少症。LC 与肠道菌群的深刻变化以及肠道屏障防御机制的不同水平的损伤有关。肠道菌群失调是指由于组成肠道菌群的细菌种类和数量减少,导致肠道菌群多样性降低的状态。LC 中肠道屏障的严重紊乱可导致肠道菌群失调、多种细菌感染、LC 相关并发症和肌肉减少症。在这篇综述中,我们将总结目前关于 LC 患者肌肉减少症与肠道菌群失调之间关系的知识。